Dr. Lal Path Labs Ltd.

rs 30

pany 70+ years of experience in the field of diagnostics 85.7 Mn patients serviced in last 5 years 30 NABL accredited Labs; National Reference Lab accredited by CAP As on March 31, 2021 Classificati

15%

in in the country with PAN India presence and consistent track record of quality and growth 15% 3 Year Revenue CAGR 22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21 ~86% ROCE Excl. C

22%

N India presence and consistent track record of quality and growth 15% 3 Year Revenue CAGR 22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21 ~86% ROCE Excl. Cash & Investments 231 La

200%

consistent track record of quality and growth 15% 3 Year Revenue CAGR 22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21 ~86% ROCE Excl. Cash & Investments 231 Labs; Geographically spr

86%

and growth 15% 3 Year Revenue CAGR 22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21 ~86% ROCE Excl. Cash & Investments 231 Labs; Geographically spread out network Rs. 331 crore (Net

Rs. 331 crore

for FY 20-21 ~86% ROCE Excl. Cash & Investments 231 Labs; Geographically spread out network Rs. 331 crore (Net) Cash & Investments as on 31st Dec, 21 5,008 Pathology & Radiology tests; Comprehensive

9.8%

Indian healthcare industry As on March 31, 2021 Classification: Restricted 5 Q3 FY22 Snapshot 9.8% INR 496.9 Cr Revenues 28.1% INR 438.1 Cr Non Covid Revenues 21.1% 6.6 Mn Patients Margin 2

INR 496.9

n healthcare industry As on March 31, 2021 Classification: Restricted 5 Q3 FY22 Snapshot 9.8% INR 496.9 Cr Revenues 28.1% INR 438.1 Cr Non Covid Revenues 21.1% 6.6 Mn Patients Margin 28.5% INR 14

28.1%

s on March 31, 2021 Classification: Restricted 5 Q3 FY22 Snapshot 9.8% INR 496.9 Cr Revenues 28.1% INR 438.1 Cr Non Covid Revenues 21.1% 6.6 Mn Patients Margin 28.5% INR 141.8 Cr Normalised

INR 438.1

rch 31, 2021 Classification: Restricted 5 Q3 FY22 Snapshot 9.8% INR 496.9 Cr Revenues 28.1% INR 438.1 Cr Non Covid Revenues 21.1% 6.6 Mn Patients Margin 28.5% INR 141.8 Cr Normalised EBITDA* 25.

21.1%

ricted 5 Q3 FY22 Snapshot 9.8% INR 496.9 Cr Revenues 28.1% INR 438.1 Cr Non Covid Revenues 21.1% 6.6 Mn Patients Margin 28.5% INR 141.8 Cr Normalised EBITDA* 25.3% 16.9 Mn Samples Margin

28.5%

% INR 496.9 Cr Revenues 28.1% INR 438.1 Cr Non Covid Revenues 21.1% 6.6 Mn Patients Margin 28.5% INR 141.8 Cr Normalised EBITDA* 25.3% 16.9 Mn Samples Margin 16.8% INR 83.6 Cr Normalised P

“Through this, we aim to ensure a seamless and convenient experience for our patients, allowing them to book tests and receive their reports at a touch of their fingers on their smartphones, iPads, laptops, etc..” Commenting results announcement, Dr.”

“We will be spending our energies brand augmenting infrastructure.”

“The consumer connect in diagnostic It will be a prime services is paramount.”

“Technology and interoperability with other constituents in the healthcare stack will be key and as an entity, we will be prepared.” dedicated teams working have in “This strong growth in Non Covid revenue is led by patient volumes.”

Subject

1

Managing Director said

1

Chief Executive Officer said

1

Subject

Investors Presentation on Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2021 Dear Sir/Madam, Please find attached a copy of Company's Q3 & 9M FY22 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2021, approved by the Board of Directors in their meeting held on February 10, 2022. We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Rajat Kalr Company Secretary and Legal Head Encl: As above . ss1 c,.non: Tntrrnal - � · egd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-IS, Roh1nt, New Delhi - 110085 +91-11-30258600 Fax· +91-11-2788-2134 · · Corporate &Mee: /1'.a1 PathLabs Ltd., 12th Floor, Tower 8, SAS Tower, Medlclty, Sector-38, Gurugram - 122 001, Haryana +91-124-3016-500. Fax: +91-124-4234-468 E-mail:

Chief Executive Officer said

the on to on the our “The coming months will see the fruition of our agreement Suburban incorporate Diagnostics brand. We will be spending our energies brand augmenting infrastructure. That is the lifeblood of our model. The consumer connect in diagnostic It will be a prime services is paramount. objective to work with our franchisee partners to bring the DLPL and Suburban Diagnostic brands closer to patients. The coming quarters shall see revitalized approach to managing the patient’s relationship with the brand digitally. We on strengthening these processes and incremental improvements are already being rolled out. Technology and interoperability with other constituents in the healthcare stack will be key and as an entity, we will be prepared.” dedicated teams working have in “This strong growth in Non Covid revenue is led by patient volumes. I am glad to share with you that our Non Covid business sees further acceleration growth momentum as compared to previous quarters. This is in